Main Article Content
Breast cancer is a type of tumor in which individual cases deviate from each other in morphology, protein expression, molecular phenotype, genetic characteristics, and prognosis. Worldwide, breast cancer is the most-common invasive cancer in women. A patient with breast cancer may have the following symptoms:- lumps, skin dimples, nipple discharge, nipple height, nipple withdrawal, pain and burning sensation. There are many causes and risks of breast cancer, including family history (heriditary), obesity, active smoking, early and late childbearing, breast feeding for less than two weeks, exposure to estrogen and oral contraceptive pills. Most breast cancers are diagnosed through estrogen receptor (ER) -positive determination and rely on estrogen for cell growth and survival. Breast cancer treatment has encountered a few progressions in the previous decades with the revelation of explicit prescient prognostic biomarkers that make conceivable the use of individualized treatments. Blocking estrogen biosynthesis by aromatase inhibitors (AI) has, subsequently, become a first-line endocrine treatment for menopausal ladies with ER-positive breast disease. Various conventional diagnosing and treating methods of breast cancer is available but there have limitation of accuracy and treating. For that reason now a day’s various biomarkers like Molecule or Biochemical biomarkers like Estrogen receptor, Progesterone receptor, human epidermal growth factor receptor 2 (HER2), human Mammaglobin (H-MAM), Osteopontin, Fibroblast Growth Factor Receptor 2 (FGFR2), Phosphatase and tensin homolog (PTEN), Physiologic Biomarkers like Carcinoma Antigen 15-3(CA 15–3), Cancer Antigen 125 (CA 125), Prostate specific antigen (PSA) and Anatomic Biomarkers Oncotype Dx, and Cystic fibrosis Trans-membrane conductance regulator (CFTR). These biomarkers are of great importance in the evaluation and diagnosis process, which leads to better patient’s care and protection of the patients. Due to its various advantages, biomarkers are considered as an innovative tool in the progression of breast cancer diagnosis and treatment.
Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk factors and preventions of breast cancer. International Journal of Biological Sciences. 2017;13(4):1387-1397.
Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer: Targets and Therapy. 2019;11:151-164.
Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: An overview. Journal of Advanced Pharmaceutical Technology and Research. 2010;1(2):109-126.
Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast cancer: Conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer Basic Clin Res [Internet]. 2015;9(2):17-34.
Al-Hilli Z, Boughey JC. The timing of breast and axillary surgery after neoadjuvant chemotherapy for breast cancer. Chinese Clinical Oncology. 2016;5(3):435.
Dhankhar R, Vyas SP, Jain AK, Arora S, Rath G, Goyal AK. Advances in novel drug delivery strategies for breast cancer therapy. Artificial Cells, Blood Substitutes, and Biotechnology. 2010;38(5):230-249.
Albain K, Anderson S, Arriagada R, Barlow W, Bergh J, Bliss J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet. 2012;379(9814):432-444.
Callahan R, Hurvitz S. Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced and recurrent disease. Curr Opin Obstet Gynecol. 2011;23(1):37-43.
McCarthy JF, Shugart LR. Biomarkers of environmental contamination. Biomarkers of Environmental Contamination. 2018;33(24):2600-2608.
Filipovic S, Filipovic A, Pejcic I, Vrbic S, Stanojevic Z, Misic I. Biomarkers in breast cancer. Jugosl Med Biohemija [Internet]. 2006;25(4):355–61.
Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy forwomenwith early-stage invasive breast cancer: American Society of clinical oncology clinical practice guideline. J Clin Oncol. 2016;34(10):1134-1150.
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373:2005-2014.
Naoi Y, Noguchi S. Multi-gene classifiers for prediction of recurrence in breast cancer patients. Breast Cancer. 2016;23: 12-18.
Younes M, Honma N. Estrogen receptor β. Arch Pathol Lab Med. 2011;135(1):63- 6.
Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics. 2006;7(8): 497-508.
Krause M, Wheeler TL, Snyder TE, Richter HE. Local effects of vaginally administered estrogen therapy: A review. Journal of Pelvic Medicine and Surgery. 2009;15(3):105-114.
Rozenbaum H. Advantages and disadvantages of estrogen treatment by transdermal or oral administration. In: European Journal of Obstetrics and Gynecology and Reproductive Biology. 1996;65(1996):33-37.
Allen WM. My life with progesterone. American Journal of Obstetrics and Gynecology. 2005;193(4):15.
Spitz I. Mechanism of action and clinical effects of antiprogestins on the non-pregnant uterus. Hum Reprod Update [Internet]. 1998;4(5):584–93.
Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: Mechanisms of action and clinical applications. Human Reproduction Update. 2005;13(3):222-30.
Micks E, Raglan GB, Schulkin J. Bridging progestogens in pregnancy and pregnancy prevention. Endocr Connect. 2015;4(4): R81-R92.
Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Mol Biol Int. 2014;852748:9.
Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers. 2017;9(5):52.
Wu M, Shu J. Multimodal molecular imaging: Current status and future directions. Contrast Media and Molecular Imaging. 2018;1382183.
Furrer D, Sanschagrin F, Jacob S, Diorio C. Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens. American Journal of Clinical Pathology. 2015;144:683-703.
Sasaroli D, Coukos G, Scholler N. Beyond CA125: The coming of age of ovarian cancer biomarkers. Biomarkers in Medicine. 2009;1(4):513-523.
Kabel AM, Al-shehri AH, Madani BS, Al-shafie SI, Amasha SA. Tumor markers of breast cancer: Role in early diagnosis, monitoring response to therapy and determination of prognosis. J Cancer Res Treat. 2016;4(5):80-87.
David JM, Hamilton DH, Palena C. MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition. Oncoimmunology. 2016;5(4).
Bahrami-Ahmadi A, Makarian F, Mortazavizadeh MR, Yazdi MF, Chamani M. Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients. J Res Med Sci. 2012;17(9):850-4.
Lee JS, Park S, Park JM, Cho JH, Kim S Il, Park BW. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers. Breast Cancer Res Treat. 2013;141(3).
Zhang M, Zhang Y, Fu J, Zhang L. Serum CA125 levels are decreased in rectal cancer but increased in fibrosis-associated diseases and in most types of cancers. In: Progress in Molecular Biology and Translational Science. 2019;162:241-252.
Pepin K, Carmen M del, Brown A, Dizon DS. CA 125 and epithelial ovarian cancer: Role in screening, diagnosis and surveillance. Am J Hematol / Oncol. 2014;10(6):22-29.
Zaviacic M. Prostate-specific antigen and history of its discovery. Bratislavské lekárske listy. 1997;98(12):659-62.
Gupta N, Sudhakar DVS, Gangwar PK, Sankhwar SN, Gupta NJ, Chakraborty B, et al. Mutations in the prostate specific antigen (PSA/KLK3) correlate with male infertility. Sci Rep. 2017;7:11225.
Cabarkapa S, Perera M, McGrath S, Lawrentschuk N. Prostate cancer screening with prostate-specific antigen: A guide to the guidelines. Prostate International. 2016;4(4):125-129.
Stenman UH. Prostate-specific antigen, clinical use and staging: An overview. Br J Urol. 1997;9(2):83-84.
Manjili MH, Najarian K, Wang XY. Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis. Future Oncology. 2012;8(6):703-711.
McVeigh TP, Hughes LM, Miller N, Sheehan M, Keane M, Sweeney KJ, et al. The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre. Eur J Cancer. 2014;50(16):2763-2770.
Hanna MG, Bleiweiss IJ, Nayak A, Jaffer S. Correlation of Oncotype DX recurrence score with histomorphology and immunohistochemistry in over 500 patients. Int J Breast Cancer. 2017;(1257078):6.
Saha A, Harowicz MR, Wang W, Mazurowski MA. A study of association of Oncotype DX recurrence score with DCE-MRI characteristics using multivariate machine learning models. J Cancer Res Clin Oncol. 2018;144(5):799-807.
Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. Breast cancer-major changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA Cancer J Clin. 2017;67(4):290-303.
Hanrahan JW. Cystic fibrosis transmembrane conductance regulator. Advances in Molecular and Cell Biology; 2004.
Schmidt BZ, Haaf JB, Leal T, Noel S. Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: Current perspectives. Clinical Pharmacology: Advances and Applications. 2016;8:127-140.
van Meegen MA, Terheggen SWJ, Koymans KJ, Vijftigschild LAW, Dekkers JF, van der Ent CK, et al. CFTR-mutation specific applications of CFTR-directed monoclonal antibodies. J Cyst Fibros. 2013;12(5):487-96.
Hull J. Cystic fibrosis transmembrane conductance regulator dysfunction and its treatment. Journal of the Royal Society of Medicine. 2012;105(2):S2-S8.
Al Joudi FS. Human mammaglobin in breast cancer: A brief review of its clinical utility. Indian Journal of Medical Research. 2014;139(5):675-685.
Galvis-Jiménez JM, Curtidor H, Patarroyo MA, Monterrey P, Ramírez-Clavijo SR. Mammaglobin peptide as a novel biomarker for breast cancer detection. Cancer Biol Ther. 2013;14(4):327-332.
Chauhan P, Yadav R. Evaluation of serum biochemical profile of breast cancer patients. Int J Med Res Heal Sci. 2016;5(7):1-7.
O’Regan A, Berman JS. Osteopontin: A key cytokine in cell-mediated and granulomatous inflammation. International Journal of Experimental Pathology. 2000;81(6):373-390.
Doyle KP, Yang T, Lessov NS, Ciesielski TM, Stevens SL, Simon RP, et al. Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke. J Cereb Blood Flow Metab. 2008;28(6): 1235-48.
Yunt ZX, Aschner Y, Brown KK. Biomarkers in IPF. In: Idiopathic Pulmonary Fibrosis. 2019;99-112.
Zhu Y, Jia H, Chen J, Cui G, Gao H, Wei Y, et al. Decreased osteopontin expression as a reliable prognostic indicator of improvement in pulmonary tuberculosis: Impact of the level of interferon-γ-Inducible protein 10. Cell Physiol Biochem. 2015;37:1983-1996.
Asch S, Sugarman JL. Epidermal nevus syndromes. In: Handbook of Clinical Neurology. 2015;132:291-316.
Lazarous DF, Shou M, Stiber JA, Dadhania DM, Thirumurti V, Hodge E, et al. Pharmacodynamics of basic fibroblast growth factor: Route of administration determines myocardial and systemic distribution. Cardiovasc Res. 1997;36(1): 78-85.
Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: The current landscape and barriers to clinical application. Oncotarget. 2017;8(9):16052-16074.
Katoh Y, Katoh M. FGFR2-related pathogenesis and FGFR2-targeted therapeutics (review). International Journal of Molecular Medicine. 2009;23(3):307- 11.
Huang T, Liu D, Wang Y, Li P, Sun L, Xiong H, et al. FGFR2 promotes gastric cancer progression by inhibiting the expression of Thrombospondin4 via PI3K-Akt-Mtor pathway. Cell Physiol Biochem. 2018;50:1332-1345.
Shi Y, Paluch BE, Wang X, Jiang X. PTEN at a glance. J Cell Sci. 2012;125(20):4687-4692.
Boosani CS, Agrawal DK. PTEN modulators: A patent review. Expert Opinion on Therapeutic Patents. 2013;23(5):569-580.
Hlobilková A, Knillová J, Bártek J, Lukás J, Kolár Z. The mechanism of action of the tumour suppressor gene PTEN. Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia. 2003;147(1):19-25.
McLoughlin NM, Mueller C, Grossmann TN. The therapeutic potential of PTEN modulation: Targeting strategies from gene to protein. Cell Chemical Biology. 2018;25(1):19-29.